MA-EVALUATE
4.6.2019 14:02:06 CEST | Business Wire | Press release
The $1.18tr forecast for the 2024 global prescription drug market reflects the role new technologies will play in addressing unmet medical needs, as strong expectations for immuno-oncology products and emerging cell and gene therapies drive growth. In 2018, new molecule approvals from the FDA reached their highest level in over a decade, and the projected CAGR of 6.9% from 2019-2024 significantly outpaces the 2.3% CAGR seen from 2010-2018.
Growth Drivers:
- 2018 saw 62 FDA approvals for novel drugs, an increase over the 55 approvals in 2017
- Oncology therapies to reach $237bn in 2024, with a CAGR of 11.4%
- Orphan Drugs will contribute an additional $109bn in sales in 2024, compared to 2018
However, as more new technologies reach the market, drug pricing pressure may continue to intensify and dampen the overall sales outlook. R&D spending is also forecast to grow more slowly from 2019-2024 than in prior years, and decrease as a proportion of overall sales – a sign of either increasing R&D efficiency, or of companies focusing on smaller indications with lower clinical development costs.
Growth Brakes:
- $198bn in sales are at risk between 2019 and 2024, due to patent expirations
- Anti-rheumatics sales decline as Humira, Enbrel and Remicade face competition
- R&D as a proportion of prescription sales is forecast to decline from 21.6% in 2018 to 18% in 2024
“Scientific advancements and health technologies are converging to deliver new options for patients, while challenging traditional drug development and commercialisation models,” said report author Ryan Waters. “The question is, which companies are best poised to take advantage of the evolving pharmaceutical market?”
Top Performers:
- Pfizer will be the leading prescription drug company in 2024, with projected sales of $51.2bn
- Keytruda is forecast to be the top selling drug in 2024, as Humira slips in the face of biosimilars
- Johnson & Johnson overtakes Roche to be the biggest spender on pharmaceutical R&D in 2024
Download your complimentary copy of the “EvaluatePharma® World Preview 2019, Outlook to 2024” at https://www.evaluate.com/thought-leadership/pharma/evaluatepharma-world-preview-2019-outlook-2024 , or visit us at Booth #2243 at the BIO International Convention, June 3-6, in Philadelphia, PA.
About Evaluate Ltd.
Evaluate provides trusted commercial intelligence for the pharmaceutical and medical device industries. Our EvaluatePharma® and EvaluatePharma Vision online subscription services provide a seamless view of the past, present and future of the global pharmaceutical market in a single, standardised platform.
Vantage – our award-winning, independent editorial team – provides thought-provoking news and insights into the current and future developments in the industry.
Evaluate has been a partner to industry-leading organisations for over 20 years. For more information on how we give our clients the time and understanding to drive better decisions, visit www.evaluate.com .
Follow us on Twitter: @EvaluatePharma, @Vantageanalysis
View source version on businesswire.com: https://www.businesswire.com/news/home/20190604005091/en/
Contact:
Media Contact: Evaluate and Vantage Jennifer Dinkel +1 617-936-7783 jennifer.dinkel@evaluate.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
MASARAT Mobility Park Welcomes FPI Gulf as Anchor Tenant for Advanced Automotive Parts Manufacturing10.2.2026 08:48:00 CET | Press release
MASARAT Mobility Park has entered into a development lease agreement with FPI Gulf to establish an automotive parts manufacturing facility, marking a key milestone in the Park’s development. This agreement strengthens MASARAT Mobility Park’s position as the premier destination for localizing the automotive and mobility value chain in Saudi Arabia. At the PIF Private Sector Forum 2026, MASARAT Mobility Park announced the signing of a development lease agreement with Fortune Parts Industry Gulf (FPI Gulf), a Joint venture between Thailand based FPI Group and local partner Fuel Autoparts Company. This milestone represents a significant step in the Park’s development and supports the localization of automotive manufacturing in the Kingdom, in line with Vision 2030. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260211304060/en/ From left to right: Noppawit Tanadumrongsak, Managing Director of FPI India; Abdulrahman Binmahfooz, M
MASARAT Mobility Park Announced Agreements with TASARU Supplier Hub to Advance Automotive Manufacturing Localization10.2.2026 08:11:00 CET | Press release
MASARAT Mobility Park signed development-lease agreements with TASARU Supplier Hub to accelerate industrial localization and strengthen Saudi Arabia’s automotive supply chain. These agreements enable TASARU Supplier Hub to establish operations at MASARAT Mobility Park to host leading automotive suppliers, reinforcing the Park’s role as a premier destination for automotive and mobility industries. MASARAT Mobility Park, Saudi Arabia’s premier destination for automotive and mobility industries, has entered into development lease agreements with TASARU Supplier Hub, a strategic initiative by TASARU Mobility Investments (a PIF company) This partnership underpins long-term industrial localization, reinforces the national automotive supply chain, and significantly enhances the Park’s value proposition for Original Equipment Manufacturers (OEMs) and suppliers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260210736469/en/ From lef
Dealroom and NATO Innovation Fund: European Defence, Security & Resilience Startups Smash Record with $8.7B Raised in 202510.2.2026 07:05:00 CET | Press release
The 55% year on year surge was fuelled by late-stage mega rounds, indicating a maturing ecosystem to address NATO’s capability needs.Munich retained its position as Europe's #1 DSR hub, with the UK attracting the most VC funding and Central and Eastern Europe showing the largest growth.AI dominated the sector, underpinning 44% of all DSR funding. An exclusive new report by Dealroom and the NATO Innovation Fund shows that European DSR (Defence, Security and Resilience) startups secured a record $8.7 billion in venture capital in 2025. The surge was fuelled by late-stage mega-rounds to support breakthrough technologies that help address critical capabilities for NATO nations – from freedom of operations & mobility, to awareness and decision making, and the security of critical technologies. Record funding surge powers DSR Startups to meet NATO nations’ most urgent security needs Funding for DSR startups increased by 55% year on year and is nearly four times higher than five years ago. It
4Moving Biotech Announces the Closing of a €12 Million Financing to Advance a First-in-Class DMOAD in Knee Osteoarthritis10.2.2026 06:52:00 CET | Press release
- Funding secured, extending the financial runway to reach a proof-of-concept inflection point - Company’s attractiveness reinforced through the onboarding of new investors 4Moving Biotech (4MB), a clinical-stage biotechnology company and a spin-off of 4P-Pharma, developing a first-in-class disease-modifying osteoarthritis drug (DMOAD) for knee osteoarthritis, today announced the closing of a €12 million financing, completed through a structured and coordinated funding process. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260209500141/en/ Francis Berenbaum (Left) Luc Boblet, Revital Rattenbach, Jérôme Vailland (Right) This financing was secured from a pool of private investors and family offices, who chose to reinforce their commitment by investing directly at the subsidiary level in 4MB. The round includes a combination of equity and loans, reflecting a flexible capital structure aligned with long-term value creation. Thi
SBTS and ZIM Connections Bring Travel eSIM to Global Travelers10.2.2026 05:00:00 CET | Press release
New service leverages SoftBank Corp.’s wireless network in Japan SBTS, the joint venture between BTS and SoftBank Corp., and ZIM Connections today announced a strategic partnership to launch a travel eSIM solution, initially focused on inbound and outbound travel into and from Japan. The service is now live and commercially available here, marking the first step in a broader global rollout of multiple travel eSIM offerings. The initial launch is a digital travel eSIM platform developed by ZIM Connections and commercialized by SoftBank Corp. (“SoftBank”), a Japan-based telecommunications and IT operator. It enables travelers to easily search for, purchase, and activate unlimited global eSIM plans through a seamless digital experience. The first phase focuses on travelers visiting Japan as well as Japan-based travelers going abroad, leveraging SoftBank’s network for connectivity in the region. This launch represents a fully commercial market introduction, delivering immediate value to tr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom